ElsaLys Biotech
France-based developer of therapeutic monoclonal antibodies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
€270k | Grant | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (60 %) | 1981 % | (98 %) | 10271 % | (2 %) | 54 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (18953 %) | (1045 %) | (51229 %) | (702 %) | (588 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (18918 %) | (1018 %) | (54329 %) | (497 %) | (668 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
ElsaLys Biotech operates as a clinical-stage immuno-oncology company, originating in Lyon, France. Founded in 2013, the firm concentrates on engineering and advancing a new class of therapeutic antibodies designed to act on tumors and their specific immune and vascular microenvironments. The company was co-founded by Christine Guillen, who also served as the CEO.
The company's business model revolves around its research and development platform which spans from clinical development to the commercialization of immune-based therapies. ElsaLys Biotech aims to provide new treatment options for patients for whom existing therapies have become less effective or have failed. The company's strategy involves converting novel therapeutic targets into viable drug candidates by leveraging a strong network of academic partners. A significant milestone was the acquisition of the company by the Italian pharmaceutical group Mediolanum Farmaceutici on May 7, 2020, which was intended to bolster the group's R&D capabilities and international expansion. Prior to its acquisition, ElsaLys Biotech had secured approximately $5.76 million in funding from investors including Bpifrance, Sofimac Investment Managers, and Transgene.
ElsaLys Biotech's product pipeline includes several proprietary development programs. A key product is Inolimomab (LEUKOTAC®), an immunotherapy monoclonal antibody targeting the interleukin-2 receptor (IL-2). This antibody is aimed at treating steroid-refractory acute Graft-versus-Host Disease (aGvHD), a severe complication that can arise after stem cell transplants. Another area of focus is the development of anti-CD160 antibody variants. One variant, ELB011, possesses both anti-angiogenic and anti-inflammatory properties for treating vascular eye diseases like Age-related Macular Degeneration (AMD). Another variant, ELB021, is designed to inhibit the formation of new blood vessels and reactivate the anti-tumor immune response, offering a complementary pathway to existing immune checkpoint inhibitors.
Keywords: immuno-oncology, therapeutic antibodies, clinical-stage biotech, oncology, cancer treatment, vascular microenvironment, Mediolanum Farmaceutici, Christine Guillen, Inolimomab, LEUKOTAC, Graft-versus-Host Disease, aGvHD, anti-CD160, monoclonal antibodies, drug development, biopharmaceutical, Lyon, France, eye diseases, tumor growth